DICE Therapeutics, Inc.
DICE · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $1,125 | $863 | $5,775 |
| % Growth | -100% | 30.4% | -85.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $1,125 | $863 | $5,775 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $62,559 | $36,506 | $19,580 | $15,715 |
| G&A Expenses | $25,662 | $12,222 | $5,004 | $3,607 |
| SG&A Expenses | $25,662 | $12,222 | $5,004 | $3,607 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $88,221 | $48,728 | $24,584 | $19,322 |
| Operating Income | -$88,221 | -$47,603 | -$23,721 | -$13,547 |
| % Margin | – | -4,231.4% | -2,748.7% | -234.6% |
| Other Income/Exp. Net | $4,334 | -$1,356 | -$18 | $609 |
| Pre-Tax Income | -$83,887 | -$48,959 | -$23,739 | -$12,938 |
| Tax Expense | -$2,223 | -$487 | $13 | $26 |
| Net Income | -$81,664 | -$48,472 | -$23,752 | -$12,964 |
| % Margin | – | -4,308.6% | -2,752.3% | -224.5% |
| EPS | -2.07 | -3.91 | -1.02 | -0.56 |
| % Growth | 47.1% | -283.3% | -82.1% | – |
| EPS Diluted | -2.07 | -3.91 | -1.02 | -0.56 |
| Weighted Avg Shares Out | 39,401 | 12,384 | 23,225 | 23,225 |
| Weighted Avg Shares Out Dil | 39,401 | 12,384 | 23,225 | 23,225 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,213 | $136 | $139 | $635 |
| Interest Expense | $679 | $174 | $13 | $26 |
| Depreciation & Amortization | $5,213 | $136 | $836 | $1,341 |
| EBITDA | -$83,008 | -$48,649 | -$22,885 | -$12,206 |
| % Margin | – | -4,324.4% | -2,651.8% | -211.4% |